178 related articles for article (PubMed ID: 30092727)
21. Safety Assessment of Alkyl PEG/PPG Ethers as Used in Cosmetics.
Fiume MM; Heldreth B; Bergfeld WF; Belsito DV; Hill RA; Klaassen CD; Liebler DC; Marks JG; Shank RC; Slaga TJ; Snyder PW; Andersen FA
Int J Toxicol; 2016 Jul; 35(1 Suppl):60S-89S. PubMed ID: 27383199
[TBL] [Abstract][Full Text] [Related]
22. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products.
Fruijtier-Pölloth C
Toxicology; 2005 Oct; 214(1-2):1-38. PubMed ID: 16011869
[TBL] [Abstract][Full Text] [Related]
23. Identification and reduction of ion suppression effects on pharmacokinetic parameters by polyethylene glycol 400.
Weaver R; Riley RJ
Rapid Commun Mass Spectrom; 2006; 20(17):2559-64. PubMed ID: 16878337
[TBL] [Abstract][Full Text] [Related]
24. A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat.
Banfor PN; Gintant GA; Lipari JM; Zocharski PD
J Pharmacol Toxicol Methods; 2016; 82():62-67. PubMed ID: 27432021
[TBL] [Abstract][Full Text] [Related]
25. Obstacles and pitfalls in the PEGylation of therapeutic proteins.
Gaberc-Porekar V; Zore I; Podobnik B; Menart V
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):242-50. PubMed ID: 18283612
[TBL] [Abstract][Full Text] [Related]
26. PEGylation of therapeutic proteins.
Jevsevar S; Kunstelj M; Porekar VG
Biotechnol J; 2010 Jan; 5(1):113-28. PubMed ID: 20069580
[TBL] [Abstract][Full Text] [Related]
27. Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages.
Schoenbrunn A; Juelke K; Reipert BM; Horling F; Turecek PL
Front Immunol; 2022; 13():894411. PubMed ID: 35967311
[TBL] [Abstract][Full Text] [Related]
28. Anti-polyethyleneglycol antibody response to PEGylated substances.
Ishida T; Kiwada H
Biol Pharm Bull; 2013; 36(6):889-91. PubMed ID: 23727911
[TBL] [Abstract][Full Text] [Related]
29. Current status and prospects of polyethyleneglycol-modified medicines.
Ishihara H
Biol Pharm Bull; 2013; 36(6):883-8. PubMed ID: 23727910
[TBL] [Abstract][Full Text] [Related]
30. Safety assessment of alkyl PEG ethers as used in cosmetics.
Fiume MM; Heldreth B; Bergfeld WF; Belsito DV; Hill RA; Klaassen CD; Liebler D; Marks JG; Shank RC; Slaga TJ; Snyder PW; Andersen FA
Int J Toxicol; 2012; 31(5 Suppl):169S-244S. PubMed ID: 23064774
[TBL] [Abstract][Full Text] [Related]
31. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
[TBL] [Abstract][Full Text] [Related]
32. Analytical measurement of PEGylated molecules.
Cheng TL; Chuang KH; Chen BM; Roffler SR
Bioconjug Chem; 2012 May; 23(5):881-99. PubMed ID: 22242549
[TBL] [Abstract][Full Text] [Related]
33. The impact of PEGylation on biological therapies.
Veronese FM; Mero A
BioDrugs; 2008; 22(5):315-29. PubMed ID: 18778113
[TBL] [Abstract][Full Text] [Related]
34. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
35. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.
Becker R; Dembek C; White LA; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):775-93. PubMed ID: 23252359
[TBL] [Abstract][Full Text] [Related]
36. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats.
Delongeas JL; de Conchard GV; Beamonte A; Bertheux H; Spire C; Maisonneuve C; Becourt-Lhote N; Goldfain-Blanc F; Claude N
Regul Toxicol Pharmacol; 2010; 57(2-3):284-90. PubMed ID: 20347907
[TBL] [Abstract][Full Text] [Related]
38. Physician Awareness of Immune Responses to Polyethylene Glycol-Drug Conjugates.
McSweeney MD; Versfeld ZC; Carpenter DM; Lai SK
Clin Transl Sci; 2018 Mar; 11(2):162-165. PubMed ID: 29383836
[TBL] [Abstract][Full Text] [Related]
39. Understanding the degradation pathway of a poorly water-soluble drug formulated in PEG-400.
Kochling JD; Miao H; Young CR; Looker AR; Shannon M; Montgomery ER
J Pharm Biomed Anal; 2007 Apr; 43(5):1638-46. PubMed ID: 17224256
[TBL] [Abstract][Full Text] [Related]
40. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
Hu X; Olivier K; Polack E; Crossman M; Zokowski K; Gronke RS; Parker S; Li Z; Nestorov I; Baker DP; Clarke J; Subramanyam M
J Pharmacol Exp Ther; 2011 Sep; 338(3):984-96. PubMed ID: 21690216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
